Emmes’ Post

𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗻𝗲𝘂𝗿𝗼𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗻𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Current treatment options can alleviate symptoms but do not treat the root cause of neurodegeneration, and therefore cannot prevent its onset or progression. Neuroinflammation represents a potential therapeutic target, but further research is necessary in order to develop a greater understanding of the process and its relationship to neuronal damage. Read more about this in our white paper here: https://okt.to/d71z4T #WhitePaper #Neuroinflammation #Neurodegeneration

Biomedical research with NHPs is important for advances in neuroscience. Read more about a proposed framework for international collaboration for #NHP neuroscience #research. https://lnkd.in/gPb89p4j #neurosciene #nonhumanprimates

Today kicks off the 9th Neurological Disorders Summit in Barcelona, which will bring together neuroscientists and physicians from across the world to share their research and perspectives. With a focus on #epilepsy, #Parkinsons, #Alzheimers, and other neurological disorders, the Summit will provide an overview of the cutting-edge technologies being used to address therapeutic and theoretical issues in #neuroscience. We look forward to hearing about the new and novel research that will emerge from these collaborations and presentations, as well as the transformative impact they will have on the diagnosis, treatment, and understanding of neurological disorders. See the agenda: https://lnkd.in/e_yEZXe

🧠 Delving into the intricate web of mammalian brains! Moritz Helmstaedter (@max-planck-institute-for-brain-research-frankfurt-am-main) explores the complexity of nerve cell communication, uncovering one of the most intricate networks in existence. The rules governing the creation and operation of this network pose fascinating questions in neuroscience. In this #videopublication, he shares insights into studying the wiring of the cerebral cortex, using electron microscopy for a 3D image dataset. Contrary to popular belief, the mammalian cortex's wiring isn't random – neurons make strategic connections. This precision opens doors for further research, potentially shedding light on psychiatric diseases. 🔍 https://lnkd.in/dTE-KiAJ #Neuroscience #BrainResearch #CerebralCortex

✌🏼 NeuroClues’ Clinical Roundtables #2: Decoding Concussion with Eye movements! ⏳As a reminder, we are organizing three roundtables to discuss issues related to neurological care. Our aim is to foster an engaging environment where peers can freely discuss and share valuable insights, contributing to the advancement of neurological research. Our ultimate goal is to share these exclusive insights at the end of these roundtables during the clinical get-together we are organizing. There, you can hear first-hand the exclusive insights given during those conversations. 🧠 With that excitement in mind, we're moving forward with our second topic: Could eye movements hold the key to a more accurate patient workup when suspecting a #concussion? Stay tuned for updates on this insightful discussion! 📚For those keen on getting a head start, we invite you to delve into our literature review on the relevance of eye tracking in concussion. Link in the comments. 👇 #biomarkers #neuroscience #eyetracking 

Brain Awareness Week – running this week from 11 – 17 March – aims to increase public support and enthusiasm for brain science and inspire the next generation of brain health scientists. Here at Deallus, we can’t imagine a more exciting time to be working in neuroscience. Anna Scott, Ph.D. has written a blog to explore some of the successes and challenges in this therapy area. Read our blog here https://lnkd.in/dCCHH6hA.   Today, the outlook for pharma’s prospects in neuroscience is much brighter than the 2010s, where major successes were limited to a small number of diseases. In addition to a number of scientific breakthroughs in our understanding of the brain, investments in early-stage neuroscience drug programs saw an uptick in the late 2010s. These successes bring hope to millions of patients and their families whose lives are impacted by brain health conditions.      Neuroscience continues to be one of Deallus’ leading therapeutic areas, both in project volume and the expertise held by our consulting staff. We’ve had the privilege of partnering with many pharma organisations over the years as they navigate the challenges and complexities of drug development and commercialisation in neuroscience.    Read our blog to find out more here https://lnkd.in/dCCHH6hA   #brainawarenessweek #neuroscience #brainhealth #inspire #brainscience #sciencebreakthrough #expertise

Ready to boost your motivation? Try implementing these neuroscience-backed strategies today and watch your drive and achievement soar! #Motivation #Neuroscience #Success #psychologyofmotivation References: 1. Schultz, W. (2015). Neuronal reward and decision signals: from theories to data. Physiological reviews, 95(3), 853-951. 2. Merzenich, M. M., Van Vleet, T. M., & Nahum, M. (2013). Brain plasticity-based therapeutics. Frontiers in human neuroscience, 7, 414. 3. Berridge, K. C. (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology, 191(3), 391-431.

Neurological diseases have become a leading cause of poor health and disability worldwide, underscoring the urgent need for enhanced research and innovative approaches in #neuroscience. Despite efforts focused on advancing treatment, progress has been disappointingly slow in part due to high risk of failure and often lengthy development timelines. When neuroscience drug developers are able to demonstrate confidence with solid early-to mid-stage data, investors are more inclined to engage, recognizing substantial market potential. Learn more in this STAT article as our Chief Executive Officer Bruce Leuchter, M.D., describes a private equity model, like the one we embrace, to support the advancement of promising neurotherapeutics:  https://lnkd.in/erMQz5fP

Due to the high risk of failure and often lengthy development timelines, many investors have historically been reluctant to support the development of novel technologies for neurological diseases until early-stage clinical data demonstrate a strong likelihood of success. In this STAT article, I outline a private equity model for neurotherapeutics based on a four-step process – search, evaluate, invest, and develop. This approach, embraced by Neurvati Neurosciences, positions assets for a broad range of development opportunities. Read here: https://lnkd.in/e-8hk7mm

I am so inspired to share our newest publication now in "Neurotherapeutics" -- This special conference report reviews the key points discussed during a three-day dynamic workshop held in 2022 over three full days. Our talented team at Critical Path Institute is honored to coauthor this paper with three people with lived experience who provided inspiration and commentary that is unmatched by all other diverse stakeholders. The themes included shared learnings, and recommendations that laid the groundwork to catalyze true advancement of novel therapies and drug development tools across multiple chronic degenerative diseases that impact the nervous system. We are so grateful to our collaborators, advisors and nonprofit organization partners and especially want to acknowledge the support of our regulatory agency representatives for advancing innovative drug development tools in unprecedented ways. Kristen Swingle, Klaus Romero, Terina N. Martinez, Ph.D., Ramona Belfiore-Oshan, Martijn Muller, Yashmin Karten, Kael White, PhD, Corissa Lau, Kimberly Ward Barowicz, Erin Lowry, Sudhir Sivakumaran, Ph.D., Katie Kopil, Maria Carrillo, David Dexter, Joseph Montminy, Kevin Kwok, Jessi Keavney, CMA, MBA, Daniel Jorgensen, MD, MPH, MBA, Kevin Perkins, Jesse Cedarbaum, Cindy Zadikoff, Gennaro Pagano, Laura Gaetano https://lnkd.in/gCcbUpr6 #datasharing , #collaboration , #fda , #ema , #patientfocused , #drugdevelopment , #alzheimers , #parkinson , #duchennemusculardystrophy , #huntingtons, #ataxia